FDA Approves Cenestin For Menopause Symptoms
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Cenestin For Menopause Symptoms

CINCINNATI, OH -- March 25, 1999 -- The United States Food and Drug Administration has approved Duramed Pharmaceuticals, Inc.’s Cenestin(TM) (synthetic conjugated estrogens, A) Tablets, the new plant-derived synthetic conjugated estrogens product for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.

Cenestin will be available by prescription within 90 days in two dosage strengths -- 0.625 mg and 0.9 mg.

The average age of American women at menopause is 51. According to the American College of Obstetrics and Gynecologists, the first wave of Baby Boomer women (born 1945 to 1960) are now entering menopause and another 20 million will reach menopause in the next decade. Currently, more than 40 million women in the U.S. are over 50 and eligible to take either ERT (estrogen only) or HRT (estrogen with a progestin).

"Women today are approaching menopause as a natural transition. They have a great deal of information and seek to make decisions that are affecting their body in partnership with their physician. They like to better understand why they are taking a prescription and the source of the medication," said Dr. Florence Comite, founder, Women's Health at Yale and associate clinical professor, Yale University School of Medicine. "Having a new plant- derived estrogen allows the physician the ability to tailor the specific medication to the individual woman's preference."

Like all estrogen drug products, Cenestin should not be used in women with known or suspected pregnancy, breast cancer, or estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active thrombophlebitis, or thromboembolic disorders. Estrogens have been reported to increase the risk of endometrial carcinoma in postmenopausal women with an intact uterus. The most common adverse events reported in clinical experience with Cenestin included headache, insomnia, asthenia, nervousness, paresthesia and depression.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities